Lymphoma
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Loncastuximab Tesirine and Rituximab in High-Risk R/R Follicular Lymphoma
FEATURING
Juan Alderuccio
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Optimizing Tafa-Len in R/R DLBCL - GELTAMO Real-World Study
FEATURING
Antonio Gutierrez
- 12 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With MCL - MAVO Phase 1/2 Study
FEATURING
Austin Kim
- 2 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Real-World Outcomes With Evolving Management of CRS in CAR-T Therapy for NHL
FEATURING
Radhika Bansal
- December 13, 2024